A Review on Eisenmenger Syndrome: Pathophysiology, Investigations, and Treatment

PDF

Published: 2021-12-29

Page: 98-112


Omar Elsaka *

Department of Cardiology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Moneer Ayman Noureldean

Department of Cardiology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Mohamed Adel Gamil

Department of Cardiology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Mostafa Tarek Ghazali

Department of Cardiology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Ashraf Hamada Abd Al-Razik

Department of Cardiology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

Dalia Hisham

Department of Cardiology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

*Author to whom correspondence should be addressed.


Abstract

Background: Eisenmenger syndrome (ES) is a group of symptoms caused by a congenital cardiac abnormality that leads to extensive anatomic shunts. Hemodynamic forces cause a left-right shunt, which progresses to severe pulmonary arterial hypertension (PAH) and increased vascular resistance due to anatomic differences present at birth. The left-to-right shunt will eventually become a right-to-left shunt due to increased pulmonary vascular resistance, culminating in substantial hypoxemia and cyanosis. This exercise explores the diagnosis and treatment of Eisenmenger syndrome, as well as the role of the interprofessional team in the care of individuals with this condition.

Conclusion: This review article aims to: review the pathophysiology of Eisenmenger syndrome, identify patients at high risk for Eisenmenger syndrome, describe the physical exam findings associated with Eisenmenger syndrome, and summarise the importance of improving interprofessional care coordination to improve the delivery of care for Eisenmenger syndrome patients.

Keywords: Eisenmenger syndrome, adult congenital heart disease, pulmonary arterial hypertension-targeted therapy


How to Cite

Elsaka, O., Noureldean, M. A., Gamil, M. A., Ghazali, M. T., Abd Al-Razik, A. H., & Hisham, D. (2021). A Review on Eisenmenger Syndrome: Pathophysiology, Investigations, and Treatment. Asian Journal of Research in Medicine and Medical Science, 3(1), 98–112. Retrieved from https://globalpresshub.com/index.php/AJRMMS/article/view/1400

Downloads

Download data is not yet available.

References

Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917-28.

Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation. 2008;118(23):e714-833.

Adriaenssens T, Delcroix M, Van Deyk K, Budts W. Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome. Eur Heart J. 2006;27(12):1472-7.

Attinà D, Niro F, Garzillo G, et al. Thoracic manifestation of Eisenmenger's syndrome in adult patients: A MDCT review. Lung. 2015;193(2):173-81.

Babu-Narayan SV, Gatzoulis MA, Kilner PJ. Non-invasive imaging in adult congenital heart disease using cardiovascular magnetic resonance. J Cardiovasc Med (Hagerstown). 2007;8(1):23-9.

Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preoperative test (INOP test I): the INOP Test Study Group. Circulation. 2002;106(12 suppl 1):I76-81.

Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73(4):372-82.

Beghetti M, Galie N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53(9):733-40.

Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest. 2009;(3):745-51.

Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults. Second of two parts. N Engl J Med. 2000;342(5):334-42.

Broberg CS, Uebing A, Cuomo L, et al. Adult patients with Eisenmenger syndrome report flying safely on commercial airlines. Heart. 2007;93(12):1599-603.

Carpentier E, Mur S, Aubry E, et al. Safety and tolerability of subcutaneous treprostinil in newborns with congenital diaphragmatic hernia and life-threatening pulmonary hypertension. J Pediatr Surg. 2017;52(9): 1480-3.

Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007;120(3):301-5.

Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol. 2004;94(2):261-3.

Das BB, Wolfe RR, Chan KC, Larsen GL, Reeves JT, Ivy D. High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. Arch Pediatr Adolesc Med. 2004;158(12):1170-6.

Diller GP, Alonso-Gonzalez R, Kempny A, et al. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: Predictive value and response to disease targeting therapy. Heart. 2012;98(9):736-42.

Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115(8):1039-50.

Diller GP, Kempny A, Inuzuka R, et al. Survival prospects of treatment naive patients with Eisenmenger: A systematic review of the literature and report of own experience. Heart. 2014;100(17):1366-72.

Diller GP, Korten MA, Bauer UMM, et al, for the German Competence Network for Congenital Heart Defects Investigators. Current therapy and outcome of Eisenmenger syndrome: Data of the German National Register for congenital heart defects. Eur Heart J. 2016;37(18):1449-55.

Dyer K, Lanning C, Das B, et al. Noninvasive Doppler tissue measurement of pulmonary artery compliance in children with pulmonary hypertension. J Am Soc Echocardiogr. 2006;19(4):403-12.

Feldman J, Habib N, Radosevich J, Dutt M. Oral treprostinil in the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2017;18(15):1661-7.

Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003;91(5):632-5.

Galie N, Beghetti M, Gatzoulis MA, et al, for the Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48-54.

Gatzoulis MA, Beghetti M, Galie N, et al, for the BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127(1):27-32.

Gonzaga LR, Matos-Garcia BC, Rocco IS, et al. Effects of acute oxygen supplementation on functional capacity and heart rate recovery in Eisenmenger syndrome. Int J Cardiol. 2017;231:110-4.

Hascoet S, Baruteau A, Humbert M. 0425: Prognostic value of invasive hemodynamic parameters in Eisenmenger syndrome [abstract]. Arch Cardiovasc Dis Suppl. Jan 2016. 8(1):101-2.

Hascoet S, Baruteau AE, Humbert M, et al. Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. J Heart Lung Transplant. 2017;36(4):386-98.

Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54(1 suppl):S10-9.

Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):13S-24S.

Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-36.

Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005;111 (24):3274-80.

Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol. 2007;99(5):696-8.

Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol. 2004;93(7):943-6.

Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(2):161-9.

Ivy DD, Griebel JL, Kinsella JP, Abman SH. Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension. J Pediatr. 1998;133(3):453-6.

Kaemmerer H, Mebus S, Schulze-Neick I, et al. The adult patient with Eisenmenger syndrome: a medical update after Dana point part I: epidemiology, clinical aspects and diagnostic options. Curr Cardiol Rev. 2010;6(4):343-55.

Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail. 2012;18(5):379-84.

Kelion AD, Webb TP, Gardner MA, Ormerod OJ, Banning AP. The warm-up effect protects against ischemic left ventricular dysfunction in patients with angina. J Am Coll Cardiol. 2001;37(3):705-10.

Lammers AE, Diller GP, Odendaal D, Tailor S, Derrick G, Haworth SG. Comparison of 6-min walk test distance and cardiopulmonary exercise test performance in children with pulmonary hypertension. Arch Dis Child. 2011;96(2):141-7.

Lang RM, et al, for the American Society of Echocardiography's Nomenclature and Standards Committee, Task Force on Chamber Quantification, ACC Echocardiography Committee, AHA, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79-108.

Lange RA, Brickner ME. Improving survival in patients with Eisenmenger syndrome: Are we any closer?. Circulation. 2017;135(15):1441-3.

Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart. 2006;92(5):664-70.

Maron BA, Galie N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: a review. JAMA Cardiol. 2016;1(9):1056-65.

Matsubara H, Ogawa A. Treatment of idiopathic/hereditary pulmonary arterial hypertension. J Cardiol. 2014;64(4):243-9.

Mebus S, Schulze-Neick I, Oechslin E, et al. The adult patient with Eisenmenger syndrome: a medical update after Dana Point part II: medical treatment - study results. Curr Cardiol Rev. 2010 Nov. 6 (4):356-62.

Moceri P, Dimopoulos K, Liodakis E, et al. Echocardiographic predictors of outcome in eisenmenger syndrome. Circulation. 2012;126(12):1461-8.

Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation. 2006;114(17):1807-10.

Oechslin E, Mebus S, Schulze-Neick I, et al. The adult patient with Eisenmenger syndrome: a medical update after Dana Point part III: specific management and surgical aspects. Curr Cardiol Rev. 2010;6(4):363-72.

Onat T, Ahunbay G, Batmaz G, Celebi A. The natural course of isolated ventricular septal defect during adolescence. Pediatr Cardiol. 1998;19(3):230-4.

Raja SG, Danton MD, MacArthur KJ, Pollock JC. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. J Cardiothorac Vasc Anesth. 2007;21(2):203-7.

Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(4):697-704.

Salehian O, Schwerzmann M, Rambihar S, Silver D, Siu S, Webb G, et al. Left ventricular dysfunction and mortality in adult patients with Eisenmenger syndrome. Congenit Heart Dis. 2007 May-Jun. 2 (3):156-64.

Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. 2001;164(9):1682-7.

Schulze-Neick I, Gilbert N, Ewert R, et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: First open prospective multicenter study of bosentan therapy. Am Heart J. 2005;150(4):716.

Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151(4):851.e1-5.